|
Volumn 4, Issue 3, 2001, Pages 223-230
|
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease
|
Author keywords
Alzheimer's disease; Brain imaging; Cholinesterase inhibitor; Dementia; Positron emission tomography (PET); Rivastigmine
|
Indexed keywords
CARBAMIC ACID DERIVATIVE;
CHOLINESTERASE INHIBITOR;
FLUORODEOXYGLUCOSE F 18;
PLACEBO;
RIVASTIGMINE;
ADULT;
AGED;
ALZHEIMER DISEASE;
ARTICLE;
BRAIN CORTEX;
BRAIN METABOLISM;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIAGNOSTIC IMAGING;
DIAGNOSTIC PROCEDURE;
DISEASE COURSE;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
FOLLOW UP;
HIPPOCAMPUS;
HUMAN;
IN VIVO STUDY;
NEURORADIOLOGY;
POSITRON EMISSION TOMOGRAPHY;
PREFRONTAL CORTEX;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
AGED;
AGED, 80 AND OVER;
ALZHEIMER DISEASE;
BRAIN;
BRAIN CHEMISTRY;
CARBAMATES;
DOUBLE-BLIND METHOD;
FEMALE;
FLUORODEOXYGLUCOSE F18;
HUMANS;
MAGNETIC RESONANCE IMAGING;
MALE;
MIDDLE AGED;
NEUROPROTECTIVE AGENTS;
PHENYLCARBAMATES;
RADIOPHARMACEUTICALS;
TOMOGRAPHY, EMISSION-COMPUTED;
|
EID: 0035699431
PISSN: 14611457
EISSN: None
Source Type: Journal
DOI: 10.1017/S1461145701002528 Document Type: Article |
Times cited : (155)
|
References (34)
|